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2211-3355/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oAvailable online 29 December 2015 Physical activity is protective of prematuremortality and those with liver disease are at an increased risk of early
mortality. It is thus plausible to suggest that physical activity may have survival beneﬁts among those with liver
disease, but this has yet to be investigated. In a national sample, we examine the prospective association of
objectively-measured physical activity on all-cause mortality among those with liver disease. Data from the
2003–2006 National Health and Nutrition Examination Survey (with follow-up through 2011) were evaluated
(analyzed in 2015). Physical activity was assessed via accelerometry over 7 days. Liver disease was assessed
via self-report of physician diagnosis. Covariates included age, gender, race-ethnicity, serum cotinine, income-
to-poverty ratio, C-reactive protein, cholesterol medication use, blood pressuremedication use, alcohol behavior,
self-reported liver disease status, serum alanine aminotransferase (ALT), serum gamma-glutamyltransferase
(GGT) and comorbid illness. The sample included 162 adults who self-reported a physician-diagnosis of liver dis-
ease. The unweighted median follow-up period was 80.0 months (IQR = 68–91; SD = 18.0). In the sample,
12,815 person-months occurred with a mortality incidence rate of 1.09 deaths per 1000 person-months. After
adjustments, for every 10 min/day increase in moderate-to-vigorous physical activity (MVPA), participants
had an 89% reduced risk of all-cause mortality (HRadjusted = 0.11; 95% CI: 0.02–0.47; P = 0.004). There was no
evidence of moderation by alcohol behavior, ALT, GGT or Hepatitis C virus status. These ﬁndings demonstrate
that modest increases in MVPA may have survival beneﬁts among those with a self-reported liver condition.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Liver diseaseIntroduction
Emerging research provides suggestive evidence that regular partic-
ipation in physical activity (PA) may help to prevent against liver
disease (Ryu et al., 2015; Berzigotti and Saran, 2015; Whitsett and
VanWagner, 2015; Keating et al., 2015; Pinto et al., 2015; Hallsworth
et al., 2015). The most common cause of liver disease in the United
States is a spectrum of liver conditions known collectively as non-
alcoholic fatty liver disease (NAFLD). NAFLD is an obesity-related condi-
tionwith an increased prevalence of other chronic diseases (e.g., insulin
resistance) (Chen et al., 2015; Vozarova et al., 2002) and premature all-
cause mortality (Kunutsor et al., 2014). However, the extent to which
PA may favor survival beneﬁts among those with any liver disease isi, JacksonHeart Study Vanguard
, School of Applied Sciences,
ion Management, 229 Turner
915 5525.
s of Health's National Center for
1424.
. This is an open access article underless understood. As a result, the purpose of this brief studywas to exam-
ine the relationship between PA and all-causemortality risk among per-
sons with a history of liver disease.
Methods
Design
Datawere extracted from the 2003–2006National Health andNutri-
tion Examination Survey (NHANES; only available cycles with
accelerometry data). Participant data was linked to death certiﬁcate
data through December 31, 2011 from the National Death Index.
Liver disease
Participants were asked: “Has a doctor or other health professional
ever told you that you had any kind of liver condition?” Participants
who answered “yes” to this question were assessed herein. Among
these participants, evidence of antibodies against the Hepatitis C virus
was assessed with a Hepatitis C antibody test, with methodological
details described elsewhere (Smith and Yartel, 2014).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Unweighted baseline characteristics, 2003–2006 NHANES (N= 162).
Point estimates (95% CI)
MVPA, min/day 21.6 (18.5–24.6)
Age, mean yrs 53.9 (51.6–56.3)
Male, % 59.8 (52.2–67.5)
Non-Hispanic white, % 62.3 (54.8–69.8)
Income-to-poverty ratio 2.72 (2.47–2.96)
Cotinine, mean ng/mL 1.41 (0.96–1.85)
CRP, mean mg/dL 0.46 (0.33–0.59)
BMI, kg/m2 28.9 (27.8–29.9)
% Obese (BMI ≥ 30 kg/m2) 35.1 (29.0–41.0)
Comorbidities a, mean 1.91 (1.72–2.10)
ALT (U/L) 37.82 (33.3–42.3)
GGT (U/L) 60.0 (40.4–79.6)
Current liver condition, % 46.2 (38.5–54.0)
Alcohol drinks, mean/day 1.81 (1.40–2.22)
Cholesterol medication, % 17.9 (11.9–23.8)
Hypertensive medication, % 27.7 (20.8–34.7)
ALT, Alanine aminotransferase.
BMI, Body mass index.
CRP, C-reactive protein.
GGT, Gamma-glutamyltransferase.
MVPA, moderate-to-vigorous physical activity.
a The comorbid illness variable indicated the summed number of morbidities for each
participant, based on physician diagnosis of: arthritis, chronic obstructive pulmonary-
disease, coronary artery disease, heart attack, stroke, overweight/obese (measured BMI
≥ 25 kg/m2), diabetes and hypertension.
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Free-living PA was assessed during all waking hours using the
ActiGraph 7164 accelerometer. SAS (version 9.2) was used to reduce
accelerometry data to those with ≥4 days of ≥10 h/day of monitored
data and integrate it into 1 minute time intervals. Non-wear time was
identiﬁed as ≥ 60 consecutive minutes of zero activity counts, with
allowance for 1–2 min of activity counts between 0 and 100. Activity
counts/min ≥ 2020 was used as the threshold to determine time spent
at moderate-to-vigorous PA (MVPA) across the valid days (Loprinzi,
2015a).
Covariates
As described elsewhere (http://www.cdc.gov/nchs/nhanes.htm),
covariates included self-reported age (continuous; years), self-reported
gender, self-reported race-ethnicity (Mexican American, non-Hispanic
white, non-Hispanic black, and other), laboratory-determined serum co-
tinine (marker of active/passive smoking status; continuous; ng/mL),
income-to-poverty ratio (continuous), laboratory-determined C-
reactive protein (CRP; continuous, mg/dL), self-reported cholesterol
medication use (yes/no), self-reported blood pressure medication
use (yes/no), self-reported alcohol behavior (average # of alcoholic
drinks/day in past 12 months; continuous), self-reported liver
disease status (yes/no), laboratory-determined serum alanine
aminotransferase (ALT; continuous, U/L), laboratory-determined
serum gamma-glutamyltransferase (GGT; continuous, U/L) and
self-reported comorbid illness (ordinal variable).
The income-to-poverty ratio is calculated by dividing the family
income by the poverty guidelines, which is speciﬁc to the family size,
year assessed, and state of residence. High sensitivity CRP was used as
a marker of systemic inﬂammation, using latex-enhanced nephelome-
try, with samples taken prior to PA assessment. The comorbid illness
variable indicated the summed number of morbidities for each partici-
pant, based on physician diagnosis of: arthritis, chronic obstructive
pulmonary disease, coronary artery disease, heart attack, stroke, over-
weight/obese (measured BMI ≥ 25 kg/m2), diabetes and hypertension.
ALT was assessed using the LX20. In the reaction, ALT catalyzes the
reversible transamination of L-alanine and α-ketoglutarate to pyruvate
and L-glutamate. The pyruvate is then reduced to lactate in the presence
of lactate dehydrogenase (LDH)with the concurrent oxidation of NADH
to NAD. The LX20 uses an enzymatic rate method to determine the GGT
activity in serum or plasma. In the reaction, the GGT catalyzes the trans-
fer of a gamma-glutamyl group from the colorless substrate, gamma-
glutamyl-p-nitroaniline, to the acceptor, glycylglycine with production
of the colored product, p-nitroaniline.
Analysis
Statistical analyses were performed via procedures from survey data
using Stata (v.12); analyzed in 2015. All analyses included the use of
survey sample weights, clustering and primary sampling units to
account for the complex NHANES design. Cox proportional hazard
models were used to examine the association between PA and all-
cause mortality. Schoenfeld's residuals were used to verify the propor-
tional hazards assumption.
Results
In the 2003–2006 NHANES cycles, 248 adults self-reported a
physician-diagnosis of liver disease and had data on the study covari-
ates; among these 248 adults, 32 died during the follow-up period.
After excluding those with insufﬁcient (b4 days of 10+ h/day of mon-
itoring data) accelerometry data (n = 86), 162 participants remained,
with 14 deaths occurring during the follow-up period and constituted
the primary analytic sample.The unweighted median follow-up period was 80.0 months (IQR=
68–91; SD=18.0). In the sample, 12,815 person-months occurredwith
a mortality incidence rate of 1.09 deaths per 1000 person-months.
Among these 162 participants, 24 (14.8%) had a positive Hepatitis C an-
tibody test, and among these 24, 1 died during the follow-up period. No
conﬁrmatory HCV polymerase chain reaction information is available.
Table 1 displays the characteristics of the study variables.
As shown in Table 2, in an unadjusted Cox proportion model, for
every 10 min/day increase in MVPA, participants had a 63% reduced
risk of all-cause mortality (HR = 0.37; 95% CI: 0.18–0.74; P = 0.007).
After adjustments, for every 10 min/day increase in MVPA, participants
had an 89% reduced risk of all-cause mortality (HRadjusted = 0.11; 95%
CI: 0.02–0.47; P = 0.004). The proportional hazards assumption was
not violated (P = 0.24) and the Harrell's C concordance statistic was
0.86. Notably, there was no evidence of multiplicative interaction
between MVPA and ALT/GGT, markers of liver inﬂammation, with all-
cause mortality; multiplicative interaction term for MVPA and ALT
(HR = 0.94; 95% CI: 0.87–1.02; P = 0.13) and MVPA and GGT (HR =
0.98; 95% CI: 0.97–1.01; P = 0.07). Also, there was no evidence of mul-
tiplicative interaction between MVPA and alcohol consumption with
mortality (interaction term: HR = 0.55; 95% CI: 0.15–2.00; P = 0.35).
Further, when we excluded the 24 individuals with a positive Hepatitis
C antibody test, MVPA remained signiﬁcantly associated with mortality
(HR = 0.11; 95% CI: 0.02–0.58; P = 0.01).
As stated in theMethods section, prior to excluding thosewith insuf-
ﬁcient accelerometry data, 248 participants (32 died during the follow-
up period) comprised the sample. Among these 248 participants, 42
(16.9%) had a positive Hepatitis C antibody test, and among these 42,
2 died during the follow-up period. Among this slightly larger sample
(248 vs. 162), additional analyses using self-reported MVPA (described
elsewhere(Loprinzi, 2015b)) were computed. Unadjusted results
(Table 2) showed that, for every 500 MET-min-week increase (equiva-
lent to 30 min/day of MVPA), participants had a non-signiﬁcant 43%
reduced risk of all-cause mortality (HR = 0.57; 95% CI: 0.31–1.04;
P = 0.06). After adjusting for age, gender and race-ethnicity, for every
500 MET-min-week increase, participants had a 44% reduced risk of
all-cause mortality (HR = 0.56; 95% CI: 0.32–0.99; P = 0.04). After
further adjustment (i.e., covariates noted in the footnote of Table 2),
MVPA was just outside the statistical signiﬁcance level (HR = 0.54;
95% CI: 0.28–1.06; P = 0.07). These attenuated results for self-
Table 2
Weighted unadjusted and adjusted Cox proportional hazard model results examining the association between self-reported and accelerometer-assessed moderate-to-vigorous physical
activity (MVPA) with all-cause mortality among adults with a history of self-reported liver disease.
Unadjusted Adjusteda
HR 95% CI P-value HR 95% CI P-value
Accelerometer-determined MVPA, 10-min/day increase 0.37 0.18–0.74 0.007 0.11 0.02–0.47 0.004
Self-reported MVPA, 500 MET-min/week increase 0.57 0.31–1.04 0.06 0.55 .028–1.06 0.07
Results for 4 different Cox proportional hazard models are shown; an unadjusted and adjusted model when using self-reported physical activity data (N= 248), and an unadjusted and
adjusted model when using accelerometer-assessed physical activity data (N= 162).
MVPA, Moderate-to-vigorous physical activity.
MET, Metabolic equivalent of task.
HR, Hazard ratio.
a Covariates included age, gender, race-ethnicity, serum cotinine, income-to-poverty ratio, C-reactive protein, cholesterol medication use, blood pressure medication use, alcohol
behavior, self-reported liver disease status, serum alanine aminotransferase, serum gamma-glutamyltransferase and comorbid illness.
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weaker associations of self-reported MVPA with health outcomes
when compared to objectively-measured MVPA (Atienza et al., 2011).
Similar to the accelerometer-derived MVPA analyses, there was no evi-
dence of multiplicative interaction between self-reported MVPA and
ALT/GGT with all-cause mortality; multiplicative interaction term for
self-reported MVPA and ALT (HR = 1.00; 95% CI: 0.99–1.01; P = 0.73)
and self-reported MVPA and GGT (HR = 0.999; 95% CI: 0.997–1.00;
P = 0.76).
Discussion
These ﬁndings demonstrate that modest increases in MVPA may
have survival beneﬁts among those with a self-reported liver condition.
We have demonstrated thatMVPA is inversely associatedwith all-cause
mortality among those with a history of self-reported liver condition,
and alcohol use and Hepatitis C status do not appearmoderate this rela-
tionship. The potential protective effects of MVPA on mortality among
thosewith a history of liver disease may be a result of the favorable car-
diometabolic effects of MVPA engagement (Loprinzi, 2015a). Further,
MVPA itself may help to positively inﬂuence liver functioning as a result
of the simulation of lipid oxidation and inhibition of lipid synthesis in
the liver through the activation of the AMP-activated protein kinase
pathway (Lavoie and Gauthier, 2006).
These preliminary ﬁndings underscore the importance of promotion
of safe forms of MVPA among patients with liver disease. Despite the
notable strengths of this study, which include the novel investigation,
objective measure of PA and a national sample, future research should
aim to overcome the limitations of this study. For example, future stud-
ies should employ a large sample size to increase the mortality inci-
dence rate and examine the inﬂuence of PA on mortality among those
with speciﬁc liver diseases, particularly NAFLD.
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